Product news

Share this article:
Canadian health officials have approved Merck's Januvia (sitagliptin phosphate monohydrate), a once-daily, oral medication in a new class of anti-hyperglycemic agents known as DPP-4 (dipeptidyl peptidase-4) inhibitors. Januvia is approved in combination therapy with metformin, a commonly prescribed diabetes medication, to improve blood sugar (glucose) control in adult patients with type 2 diabetes when diet and exercise plus metformin do not provide adequate glycemic control.     
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.